Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Hydrogel Developed for Controlled Release of Immunotherapeutic Drugs

By LabMedica International staff writers
Posted on 21 Mar 2018
Cancer researchers have developed an injectable hydrogel designed to expedite the controlled release of a cyclic dinucleotide drug for enhanced cancer immunotherapy.

Recent advancements in the field of immunotherapy have yielded encouraging results for the treatment of advanced cancers. More...
Cyclic dinucleotides (CDNs) are a powerful new class of immunotherapy drugs known as STING (Stimulator of Interferon Genes) agonists, currently in clinical trials. However, previous studies of CDNs in mouse cancer models have demonstrated the necessity for multiple injections and improved survival only in relatively nonaggressive tumor models.

Investigators at Rice University (Houston, TX, USA) sought to improve the efficacy of CDN immunotherapy by developing a novel biomaterial. This injectable peptide hydrogel was a positively charged, MultiDomain Peptide (MDP), which self-assembled to form a nanofibrous matrix and was easily delivered by syringe. They named the material “STINGel.” STINGel was designed to localize at the tumor to provide controlled release of CDN delivery, showing an eight-fold slower release rate compared to a standard collagen hydrogel.

The investigators tested STINGel in both laboratory cultures and in vivo. They reported in the February 6, 2018, online edition of the journal Biomaterials that for the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone, with CDN-MDP alone, or with STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived.

"The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels," said senior author Dr. Jeffrey Hartgerink, professor of chemistry and bioengineering at Rice University. "Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time. The CDN we used in this study is currently in clinical trials. We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers."

Related Links:
Rice University


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.